These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 26114211

  • 1. Transfusion in CMV seronegative T-depleted allogeneic stem cell transplant recipients with CMV-unselected blood components results in zero CMV transmissions in the era of universal leukocyte reduction: a U.K. dual centre experience.
    Hall S, Danby R, Osman H, Peniket A, Rocha V, Craddock C, Murphy M, Chaganti S.
    Transfus Med; 2015 Dec; 25(6):418-23. PubMed ID: 26114211
    [Abstract] [Full Text] [Related]

  • 2. Provision of cellular blood components to CMV-seronegative patients undergoing allogeneic stem cell transplantation in the UK: survey of UK transplant centres.
    Morton S, Peniket A, Malladi R, Murphy MF.
    Transfus Med; 2017 Dec; 27(6):444-450. PubMed ID: 28913908
    [Abstract] [Full Text] [Related]

  • 3. Transfusion of CMV-unselected blood components may lead to inappropriate donor selection for patients subsequently undergoing allogeneic stem cell transplant.
    Morton S, Danby R, Rocha V, Peniket A, Murphy MF.
    Transfus Med; 2015 Dec; 25(6):411-3. PubMed ID: 26914496
    [Abstract] [Full Text] [Related]

  • 4. Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors.
    Ljungman P, Larsson K, Kumlien G, Aschan J, Barkholt L, Gustafsson-Jernberg A, Lewensohn-Fuchs I, Ringdén O.
    Scand J Infect Dis; 2002 Dec; 34(5):347-50. PubMed ID: 12069017
    [Abstract] [Full Text] [Related]

  • 5. Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study.
    Narvios AB, Lichtiger B.
    Haematologica; 2001 Jul; 86(7):749-52. PubMed ID: 11454531
    [Abstract] [Full Text] [Related]

  • 6. Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME).
    Thiele T, Krüger W, Zimmermann K, Ittermann T, Wessel A, Steinmetz I, Dölken G, Greinacher A.
    Transfusion; 2011 Dec; 51(12):2620-6. PubMed ID: 21645009
    [Abstract] [Full Text] [Related]

  • 7. Prevention of transfusion-transmitted cytomegalovirus infection using leukoreduced blood components in patients receiving seronegative umbilical cord blood transplantation.
    Shigemura T, Yanagisawa R, Komori K, Morita D, Kurata T, Tanaka M, Sakashita K, Nakazawa Y.
    Transfusion; 2019 Oct; 59(10):3065-3070. PubMed ID: 31322734
    [Abstract] [Full Text] [Related]

  • 8. Transfusion of leukoreduced cellular blood components from cytomegalovirus-unscreened donors in allogeneic hematopoietic transplant recipients: analysis of 72 recipients.
    Narvios AB, de Lima M, Shah H, Lichtiger B.
    Bone Marrow Transplant; 2005 Sep; 36(6):499-501. PubMed ID: 16044143
    [Abstract] [Full Text] [Related]

  • 9. Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients.
    Narvios AB, Przepiorka D, Tarrand J, Chan KW, Champlin R, Lichtiger B.
    Bone Marrow Transplant; 1998 Sep; 22(6):575-7. PubMed ID: 9758346
    [Abstract] [Full Text] [Related]

  • 10. Survey of current practice for prevention of transfusion-transmitted cytomegalovirus in the United States: leucoreduction vs. cytomegalovirus-seronegative.
    Smith D, Lu Q, Yuan S, Goldfinger D, Fernando LP, Ziman A.
    Vox Sang; 2010 Jan; 98(1):29-36. PubMed ID: 19695013
    [Abstract] [Full Text] [Related]

  • 11. Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters.
    van Prooijen HC, Visser JJ, van Oostendorp WR, de Gast GC, Verdonck LF.
    Br J Haematol; 1994 May; 87(1):144-7. PubMed ID: 7947238
    [Abstract] [Full Text] [Related]

  • 12. Transfusion-transmitted cytomegalovirus: behaviour of cell-free virus during blood component processing. A study on the safety of labile blood components in Switzerland.
    Voruz S, Gowland P, Eyer C, Widmer N, Abonnenc M, Prudent M, Masouridi-Levrat S, Duchosal MA, Niederhauser C.
    Blood Transfus; 2020 Nov; 18(6):446-453. PubMed ID: 32203012
    [Abstract] [Full Text] [Related]

  • 13. Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction?
    Kekre N, Tokessy M, Mallick R, McDiarmid S, Huebsch L, Bredeson C, Allan D, Tay J, Tinmouth A, Sheppard D.
    Biol Blood Marrow Transplant; 2013 Dec; 19(12):1719-24. PubMed ID: 24099958
    [Abstract] [Full Text] [Related]

  • 14. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients.
    van der Heiden PL, Kalpoe JS, Barge RM, Willemze R, Kroes AC, Schippers EF.
    Bone Marrow Transplant; 2006 Apr; 37(7):693-8. PubMed ID: 16501590
    [Abstract] [Full Text] [Related]

  • 15. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors.
    De Witte T, Schattenberg A, Van Dijk BA, Galama J, Olthuis H, Van der Meer JW, Kunst VA.
    Transplantation; 1990 Dec; 50(6):964-8. PubMed ID: 2175059
    [Abstract] [Full Text] [Related]

  • 16. Survey on Transfusion-Transmitted Cytomegalovirus and Cytomegalovirus Disease Mitigation.
    Weisberg SP, Staley EM, Williams LA, Pham HP, Bachegowda LS, Cheng YH, Schwartz J, Shaz BH.
    Arch Pathol Lab Med; 2017 Dec; 141(12):1705-1711. PubMed ID: 28849943
    [Abstract] [Full Text] [Related]

  • 17. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products.
    Nichols WG, Price TH, Gooley T, Corey L, Boeckh M.
    Blood; 2003 May 15; 101(10):4195-200. PubMed ID: 12531791
    [Abstract] [Full Text] [Related]

  • 18. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant.
    Bowden RA, Slichter SJ, Sayers MH, Mori M, Cays MJ, Meyers JD.
    Blood; 1991 Jul 01; 78(1):246-50. PubMed ID: 1648976
    [Abstract] [Full Text] [Related]

  • 19. Assessment of a cytomegalovirus serology dual-testing strategy in hematopoietic stem cell transplant recipients.
    Perry DA, Hakki M.
    Transpl Infect Dis; 2016 Oct 01; 18(5):809-814. PubMed ID: 27502917
    [Abstract] [Full Text] [Related]

  • 20. Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis.
    Vamvakas EC.
    Transfus Med Rev; 2005 Jul 01; 19(3):181-99. PubMed ID: 16010649
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.